自願公告 創新藥安奈拉唑鈉用於反流性食管炎的新適應症 III期臨床完成首例受試者入組 Sihuan Pharmaceutical Holdings Group Ltd. 四環醫藥控股集團有限公司 （於百慕達註冊成立的有限公司） （股份代號：0460） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 關於軒竹生物 軒 竹 生 物 是 四 環 醫 藥 旗 下 的 創 新 藥 子 公 司，是 一 家 根 植 於 中 國、具 有 全 球 化 視 野 的 創 新 型 制 藥 企 業，聚 焦 於 消 化、腫 瘤 及 非 酒 精 性 脂 肪 性 肝 炎 等 重 大 疾 病 領 域，致 力 於 研 發、生 產 及 商 業 化 具 有 核 心 自 主 知 識 產 權 的1類 新 藥。公 司 擁 有 一 流 的 研 發 團 隊，核 心 人 員 均 具 有 多 年 新 藥 研 發 經 驗。公 司 同 時 具 備 小 ...

Core Viewpoint - The global ESG investment is accelerating towards mainstream adoption, with investors recognizing that companies with strong ESG performance tend to have better innovation capabilities and long-term resilience, leading to more stable and sustainable investment returns [1] Group 1: Medical Aesthetics Business Growth - The medical aesthetics business of the company is experiencing explosive growth, with projected revenue of 744 million yuan in 2024, representing a year-on-year increase of 65.4% [3] - The growth is supported by continuous investment in product innovation compliance and channel deepening [3] Group 2: Product Innovation and Quality - The company has developed a product matrix for medical aesthetics, including self-developed injectable products that have received regulatory approval, focusing on quality stability, clinical efficacy, and safety [4] - The company is expanding its product line with potential new products expected to be approved in the next 1 to 3 years, including collagen and water light needles [4] Group 3: Channel Expansion and Internationalization - The company has established a dual-track model of "direct sales + agency," covering over 370 cities and collaborating with more than 6,200 medical aesthetic institutions [6] - The company is accelerating its international expansion, with successful registrations of some products in Indonesia and Malaysia, and plans to enter markets in Brazil and the Middle East [6] Group 4: Innovation in Pharmaceuticals - The company is recognized for its deep engagement in innovative drugs and biopharmaceuticals, focusing on improving drug accessibility and addressing unmet clinical needs [7] - The company has multiple innovative drugs approved for various therapeutic areas, including oncology and diabetes, with significant market potential [12] Group 5: Financial Outlook and Growth Strategy - The company aims to achieve approximately 2.3 billion yuan in revenue by 2025, with a goal of turning overall operating profit positive [13] - With a cash reserve of nearly 4 billion yuan, the company is well-positioned to support the commercialization of its new products and drive further value enhancement [13]